References
- Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al.Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccineN Engl J Med20203832726032615 1:CAS:528:DC%2BB3MXotFSjuw%3D%3D https://doi.org/10.1056/NEJMoa2034577 33301246
- Swiss Federal Office of Public Health. Status report, Switzerland and Liechtenstein. COVID-19 Switzerland: Information on the current situation. 2022. https://www.covid19.admin.ch/en/overview. Accessed 15 Nov 2023.
- Warren GW, Lofstedt R, Wardman JKCOVID-19: the winter lockdown strategy in five European nationsJ Risk Res2021243–4267293 https://doi.org/10.1080/13669877.2021.1891802
- Allam Z. The first 50 days of COVID-19: a detailed chronological timeline and extensive review of literature documenting the pandemic. Surv Covid-19 Pandemic its Implic. 2020:1–7.
- Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al.Cryo-EM structure of the 2019-nCoV spike in the prefusion conformationScience2020367648312601263 1:CAS:528:DC%2BB3cXkvFemt70%3D https://doi.org/10.1126/science.abb2507 32075877 7164637
- Dolgin EThe tangled history of mRNA vaccinesNature20215977876318324 1:CAS:528:DC%2BB3MXitVegtr%2FF https://doi.org/10.1038/d41586-021-02483-w 34522017
- Chaudhary N, Weissman D, Whitehead KAmRNA vaccines for infectious diseases: principles, delivery and clinical translationNat Rev Drug Discov20212011817838 1:CAS:528:DC%2BB3MXhvVygtL%2FP https://doi.org/10.1038/s41573-021-00283-5 34433919 8386155
- Rosa SS, Prazeres DMF, Azevedo AM, Marques MPCmRNA vaccines manufacturing: challenges and bottlenecksVaccine2021391621902200 1:CAS:528:DC%2BB3MXnsVGgtbk%3D https://doi.org/10.1016/j.vaccine.2021.03.038 33771389 7987532
- Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al.Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccineN Engl J Med20213845403416 1:CAS:528:DC%2BB3MXjvFSmsrc%3D https://doi.org/10.1056/NEJMoa2035389 33378609
- Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al.An mRNA Vaccine against SARS-CoV-2—preliminary reportN Engl J Med20203832019201931 1:CAS:528:DC%2BB3cXitleitrjL https://doi.org/10.1056/NEJMoa2022483 32663912
- Walsh EE, Frenck RW, Falsey AR, Kitchin N, Absalon J, Gurtman A, et al.Safety and immunogenicity of two RNA-based COVID-19 vaccine candidatesN Engl J Med20203832524392450 1:CAS:528:DC%2BB3cXis1yksLrM https://doi.org/10.1056/NEJMoa2027906 33053279
- Pormohammad A, Zarei M, Ghorbani S, Mohammadi M, Razizadeh MH, Turner DL, Turner RJEfficacy and safety of COVID-19 vaccines: a systematic review and meta-analysis of randomized clinical trialsVaccines202195467 1:CAS:528:DC%2BB3MXitV2rs7%2FF https://doi.org/10.3390/vaccines9050467 34066475 8148145
- Swiss Federation. 812.21: Federal Act on medicinal products and medical devices (Therapeutic Products Act, TPA) 2000. https://www.fedlex.admin.ch/eli/cc/2001/422/en. Accessed 15 Nov 2023.
- Swissmedic. Guidance document: temporary authorisation for human medicinal products HMV4. 2022. https://www.swissmedic.ch/dam/swissmedic/en/dokumente/zulassung/zl_hmv_iv/zl109_00_001d_wl_befristete_zl_ham_hmv4_ab_010121.pdf.download.pdf/ZL109_00_001e_WL_Temporary_authorisation_for_human_medicinal_products_HMV4.pdf. Accessed 15 Nov 2023.
- Swissmedic. Swissmedic grants authorisation for the first COVID-19 vaccine in Switzerland. 2020. https://www.swissmedic.ch/swissmedic/en/home/news/coronavirus-covid-19/covid-19-impfstoff_erstzulassung.html. Accessed 15 Nov 2023.
- Swissmedic. Guidance document: authorisation procedures for Covid-19 medicinal products during a pandemic HMV4. 2021. https://www.swissmedic.ch/dam/swissmedic/en/dokumente/zulassung/zl_hmv_iv/zl000_00_044d_wl_zulassungsverfahren_covid-19.pdf.download.pdf/FZL000_00_044e_WL_Guidance_document_Authorisation_procedures_for_Covid-19_medicinal_products_during_a_pandemic.pdf. Accessed 15 Nov 2023.
- Swissmedic. Swissmedic grants authorisation for the COVID-19 vaccine from Moderna. 2021. https://www.swissmedic.ch/swissmedic/en/home/news/coronavirus-covid-19/zulassung-covid-19-impfstoff-moderna.html. Accessed 15 Nov 2023.
- Bundesamt für Gesundheit (BAG) und Eidgenössische Kommission für Impffragen (EKIF). Minutes of the 83rd plenary meeting 27.01.2021. https://www.bag.admin.ch/dam/bag/de/dokumente/mt/i-und-b/ekif/protokolle-2021/protokoll-plenarsitzung-83-ekif.pdf.download.pdf/Protokoll_der_83._Plenarsitzung_vom_27.01.2021.pdf. Accessed 15 Nov 2023.
- Swissmedic. Prescribing information for Comirnaty and/or Spikevax. 2023. www.swissmedicinfo.ch
- Moderna Switzerland GmbH, Pfizer AG. Wichtige sicherheitsrelevante Information zu den mRNA-Impfstoffen gegen COVID-19 (COVID-19 Vaccine Moderna und Comirnaty): Risiko für Myokarditis und Perikarditis. Schweizerische Ärztezeitung. 2021;19:19–20.
- Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani ACGlobal impact of the first year of COVID-19 vaccination: a mathematical modelling studyLancet Infect Dis202222912931302 1:CAS:528:DC%2BB38Xhs1CkurvO https://doi.org/10.1016/S1473-3099(22)00320-6 35753318 9225255